TMEM245

Across TCGA pan-cancer cohorts, TMEM245 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM245 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM245 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM245 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where TMEM245 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.797	0.465	<.001	57	view →
CCRCC	OS	Median	All	0.908	0.766	.022	7	view →
LUAD	DFS	Median	All	0.898	1.000	.021	4	view →
PDAC	OS	Median	IV	0.937	0.395	.026	3	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.864	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM245–HNSC (DFS)

Open the HNSC breakdown →